Compare Crispr Therapeutics AG (CRSP) vs EPR Properties (EPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs EPR Properties — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while EPR Properties trades at $60.14 (market cap $4.56B). The key difference: Crispr Therapeutics AG and EPR Properties are close in size by market cap, and EPR Properties pays a 6.25% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | EPR | |
|---|---|---|
Market Cap | $4.97B | $4.56B |
Sector | Health | Real Estate |
52-Week High | $76.78 | $60.81 |
52-Week Low | $44.34 | $48.71 |
Enterprise Value | $3.32B | $7.62B |
Dividend Yield | — | 6.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
EPR Properties trades at $59.81, up 0.32% today, with a bullish technical signal from moving averages and strong fundamentals including a 39.93% net income margin and consistent dividend payments. Recent earnings show mixed results with a Q1 2026 miss but previous quarters beating expectations. The company maintains robust cash flow from operations of $421 million in 2025 and high portfolio occupancy.
Outlook remains positive with a consensus price target of $63.00, though risks include reliance on experiential real estate and market sensitivity. The stock offers a compelling blend of income and growth, supported by analyst buy ratings and recent acquisitions like the Six Flags park deal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
